Skip to main content
. 2015 Oct 14;48(2):458–464. doi: 10.4143/crt.2015.135

Fig. 3.

Fig. 3.

Spider plots of percent change in lesion sum from baseline at best response by epidermal growth factor receptor (EGFR) status in Korean patients treated with pemetrexed-cisplatin/gefitinib (A) and gefitinib monotherapy (B).